
- Volume 0 0
TEVA SETTLES PATENT CHALLENGE OF GSK DRUGS
Teva Pharmaceutical IndustriesLtd has resolved itspatent dispute with GlaxoSmithKline (GSK) via a settlement that will allow the Israel-basedgeneric drug maker to enter the US market with itsgeneric versions of 3 GSK diabetes drugs: Avandia (rosiglitazonemaleate), Avandamet (rosiglitazone maleate and metforminHCl), and Avandaryl (rosiglitazone maleate andglimepiride) oral tablets. Although details of the settlementwere held confidential by both parties, it was disclosed thatTeva could begin US marketing of the GSK drugs late in thefirst quarter of 2012. GSK filed several lawsuits challengingTeva?s plans to market generic versions of its drugs, and atrial in federal court had been scheduled to begin in August.
Articles in this issue
almost 18 years ago
Understanding the Metabolic Syndromealmost 18 years ago
LABOR DEPT SEES SLOWDOWN IN Rx COSTS, THANKS TO GENERICSalmost 18 years ago
can you READ these Rxs?almost 18 years ago
Case Studiesalmost 18 years ago
compounding HOTLINEalmost 18 years ago
HYPERTENSION WATCHalmost 18 years ago
DIABETES WATCHalmost 18 years ago
CHOLESTEROL WATCHalmost 18 years ago
ASTHMA WATCHalmost 18 years ago
ARTHRITIS WATCHNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.















































































































































































































